PL3630188T3 - Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii - Google Patents

Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii

Info

Publication number
PL3630188T3
PL3630188T3 PL18728619T PL18728619T PL3630188T3 PL 3630188 T3 PL3630188 T3 PL 3630188T3 PL 18728619 T PL18728619 T PL 18728619T PL 18728619 T PL18728619 T PL 18728619T PL 3630188 T3 PL3630188 T3 PL 3630188T3
Authority
PL
Poland
Prior art keywords
composition
novobiocin
methotrexate
therapy
combination
Prior art date
Application number
PL18728619T
Other languages
English (en)
Inventor
Marguérite MASCHA MENSONIDES-HARSEMA
Charlott BRUNMARK
Karin Von Wachenfeldt
Original Assignee
Amplio Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplio Pharma Ab filed Critical Amplio Pharma Ab
Publication of PL3630188T3 publication Critical patent/PL3630188T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18728619T 2017-05-31 2018-05-31 Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii PL3630188T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1750688 2017-05-31
PCT/EP2018/064322 WO2018220101A1 (en) 2017-05-31 2018-05-31 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
EP18728619.0A EP3630188B1 (en) 2017-05-31 2018-05-31 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy

Publications (1)

Publication Number Publication Date
PL3630188T3 true PL3630188T3 (pl) 2022-01-03

Family

ID=62492644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18728619T PL3630188T3 (pl) 2017-05-31 2018-05-31 Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii

Country Status (6)

Country Link
US (1) US11883405B2 (pl)
EP (1) EP3630188B1 (pl)
DK (1) DK3630188T3 (pl)
ES (1) ES2897200T3 (pl)
PL (1) PL3630188T3 (pl)
WO (1) WO2018220101A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112675177A (zh) * 2020-12-28 2021-04-20 南方医科大学珠江医院 包含抑制剂和甲氨蝶呤的药物组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2001064214A2 (en) 2000-02-28 2001-09-07 The University Of British Columbia Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (pl) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Pochodne kolchinolu jako inhibitory angiogenezy
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
WO2010141667A1 (en) * 2009-06-03 2010-12-09 Case Western Reserve University Therapeutic agent delivery system and method

Also Published As

Publication number Publication date
EP3630188B1 (en) 2021-08-25
ES2897200T3 (es) 2022-02-28
WO2018220101A1 (en) 2018-12-06
EP3630188A1 (en) 2020-04-08
US11883405B2 (en) 2024-01-30
US20200101074A1 (en) 2020-04-02
DK3630188T3 (da) 2021-11-15

Similar Documents

Publication Publication Date Title
IL264730A (en) A pharmaceutical preparation containing tgfbetarii and another anti-cancer preparation
SG11202003320SA (en) Dihydropyrimidine compounds and uses thereof in medicine
EP3505519A4 (en) PYRIDINAMINE-SUBSTITUTED HETEROTRICYCLO COMPOUNDS, PRODUCTION THEREOF AND USE IN MEDICINAL PRODUCTS
EP3354306A4 (en) DRUG DELIVERY DEVICE AND MEDICATION DELIVERY UNIT
EP3658554A4 (en) DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE
GB201604213D0 (en) Drug combination and its use in therapy
EP3434285A4 (en) PHARMACEUTICAL COMPOSITION AND USES THEREOF
GB201820659D0 (en) Novel compostions and their use in therapy
IL274868A (en) History of imidazopyridine and their use as medicine
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
HUE045185T2 (hu) Új terápiás vegyület és terápiában történõ alkalmazása
PL3630188T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
EP3615064A4 (en) ENRICHED CELL COMPOSITIONS AND THERAPEUTIC USE
EP3613742A4 (en) INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE
EP3458058A4 (en) PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3341481A4 (en) MICRORNA 328 ANTISENSE COMPOSITION AND THERAPEUTIC USE
GB201519644D0 (en) Therapy and pharmaceutical composition
PT3664800T (pt) Formulações terapêuticas que compreendem inibidor da cox-2 e utilizações das mesmas
EP3718543A4 (en) PHARMACEUTICAL COMPOSITION AND ITS USE
EP3474840A4 (en) USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES
CZ306966B6 (cs) Dijodo-komplexy platiny s ω-substituovanými deriváty 6-alkyloxy-9-deazapurinu a použití těchto komplexů pro přípravu léčiv v protinádorové terapii
EP3258956A4 (en) Dldh, derivatives thereof and formulations comprising same for use in medicine
IL292646A (en) Pharmaceutical combination and its use